Not checkedNot checked for notices yet.
Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial
Robert J. Motzer, Jean-François Martini, Xinmeng J. Mu and 7 more
Nature Communications · 2022
doi:10.1038/s41467-022-33555-8 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Based on the S-TRAC results, sunitinib is approved as adjuvant treatment for adult patients at high risk of recurrent RCC following nephrectomy. Here, the authors report the results of an integrated multi-omics tumor analysis of 171 patients from the trial and identify specific molecular subtypes as well as potential new targets.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.